A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors
Published: 02 September 2021
SGLT-2 inhibitors represent one of the single biggest advances in heart failure practice, but how confident are you when comes to using them in different patients, and what can we reasonably expect in the coming months and years from ongoing trials?
Watch our esteemed faculty – Prof Andrew Coats, Dr Biykem Bozkurt and Prof Carolyn Lam as they summarise the latest SGLT-2 inhibitor data in heart failure and attempt to demystify some important practical points around their use with other agents.
To conclude the session, the panel will consider best practices in light of the evidence and guidance we have available today and how to implement this in practice.
ESC Congress 2021
Key Learning Objectives
- Review recent data from randomised controlled trials and meta-analyses on the use of SGLT-2 inhibitors for HFrEF and HFpEF
- Describe parallel and sequential approaches to HFrEF management
- Recall best practice recommendations using SGLT-2 inhibitors in patients with HFrEF without type-2 diabetes
- Apply appropriate treatment algorithms to the management of HF patients
- Heart Failure Specialists
- General Cardiologists
- General Practitioners
SGLT-2 inhibitors in heart failure: Where are we now and where are we heading?
Best practice of SGLT2 inhibitors in HFrEF: A Practical Overview
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Prof Andrew Coats is President of the Heart Failure Association and Professor of Cardiology, University of Warwick, UK. He is an Australian-British academic cardiologist and inventor. Prof Coats' main interest is heart failure.
From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine of the University of Sydney.
He is an Australian-British academic cardiologist as well as a successful fundraiser, university administrator and inventor.
Prof Coats is Editor-in-Chief of the Cardiac Failure Review editorial board.
Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America.
Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine.
Professor and Senior Consultant
Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.